个人简历

乔爱君博士毕业于中国医学科学院&北京协和医学院（清华大学医学部），回国前担任美国阿拉巴马大学伯明翰分校生物工程系和糖尿病研究中心助理教授，目前任中国科学院上海药物研究所/中科中山药物创新研究院研究员，博士生导师，课题组长（PI）。乔博士长期致力于发掘调控糖脂代谢的新分子和网络通路，并探究其对2型糖尿病、非酒精性脂肪肝、肥胖、动脉粥样硬化等代谢性疾病和心血管疾病发生发展的作用，为新药开发和治疗方案提供创新思路和试验基础。

研究领域

糖尿病、肥胖、非酒精性脂肪肝以及心血管疾病发病的分子机制研究及相关疾病创新药物的开发

研究成果

乔博士目前已发表（包括修回）SCI论文24篇（含10 篇第一或通讯作者），出版专著一部（共同主编）；其中以第一或通讯作者文章发表于Circulation Research（修回即将发表），Nature Communications，Hepatology，The Journal of Cell Biology，The FASEB Journal，International Journal of Molecular Sciences，Journal of American Heart Association 等；以合作者发表文章于Journal of Hepatology，The Journal of Extracellular Vesicles, Diabetologia，Cardiovascular Research，Theranostics等杂志。发表于The Journal of Cell Biology的文章被该杂志遴选为当期亮点并同期发表了对该文的述评文章，发表于The FASEB Journal的文章很快被代谢领域专家推荐到Faculty 1000。目前担任美国心脏病协会（AHA）基金、美国密歇根州糖尿病中心探索基金和奥地利国家科学基金会基金评审专家，PLOS ONE、Front. Physiol.等多家杂志编委, Scientific Reports、Translational Research、The FASEB Journal、Journal of the European Academy of Dermatology and Venereology、Journal of Endocrinology等20多家杂志特邀评审专家。

代表性论著（*：通讯作者）

1. Aijun Qiao*, Wenxia Ma, Huadong Li, Shiyue Xu, Eric Zhang, Jiawei Shi, Chan Boriboun, Junlan Zhou, Thanh Nguyen, Xin Tong, Lei Yin, Chunxiang Zhang, Yabing Chen, Jianyi Zhang, Gangjian Qin*. Hepatic Sam68 deficiency protects against hypercholesterolemia and atherosclerosis. (*共同通讯作者，Circulation Research，修回即将发表，IF₂₀₂₂: 23.2)

2. Aijun Qiao*, Wenxia Ma, Ying Jiang, Chaoshan Han，Baolong Yan, Junlan Zhou, Gangjian Qin*. Hepatic Sam68 regulates systemic glucose homeostasis and insulin sensitivity. International Journal of Molecular Sciences. (*共同通讯作者，接收，IF₂₀₂₂: 6.2)

3. Huabing Zhang*, Guang Ren*, Aijun Qiao*. Editorial: Hepatic Glucose and Lipid Metabolism. Frontiers in Physiology, section Metabolic Physiology. (*共同通讯作者，接收, IF₂₀₂₂: 4.6)

4. Aijun Qiao*, Wenxia Ma, Jianxin Deng, Junlan Zhou, Chaoshan Han, Eric Zhang, Chan Boriboun, Shiyue Xu, Chunxiang Zhang, Chunfa Jie, Jeong-a Kim, Kirk Habegger, Hongyu Qiu, Ting C Zhao, Jianyi Zhang, Gangjian Qin*. Ablation of Sam68 in adult mice increases thermogenesis and energy expenditure. The FASEB Journal, 2021, 35(8): e21772. (*共同通讯作者, IF₂₀₂₂: 5.8).

5. Aijun Qiao, Junlan Zhou, Shiyue Xu, Wenxia Ma, Chan Boriboun, Teayoun Kim, Baolong Yan, Jianxin Deng, Liu Yang, Eric Zhang, Yuhua Song, Yongchao C. Ma, Stephane Richard, Chunxiang Zhang, Hongyu Qiu, Kirk Habegger, Jianyi Zhang, Gangjian Qin. Sam68 promotes hepatic gluconeogenesis via CRTC2. Nature Communications, 2021, 12(1):3340. (IF₂₀₂₂: 17.7)

6. Aijun Qiao#, Xiongjie Jin#, Junfeng Pang, Demetrius Moskophidis, and Nahid F. Mivech. The transcriptional regulator of the chaperone response HSF1 controls hepatic bioenergetics and protein homeostasis. Journal of Cell Biology, 2017, 216:723-741. (#共第一作者，IF₂₀₂₂: 10.5)

7. Aijun Qiao, Arineh Khechaduri, R. Kannan Mutharasan, Rongxue Wu, Varun Nagpal and Hossein Ardehali. MicroRNA-210 Decreases Heme Levels by Targeting Ferrochelatase in Cardiomyocyte. Journal of the American Heart Association, 2013, 2(2): e000121. (IF₂₀₂₂: 6.1)

8. Aijun Qiao, Jichao Liang, Yaojun Ke, Chenghong Li, Ying Cui, Lian Shen, Huabing Zhang, Anfang Cui, Xiaojun Liu, Changzheng Liu, Yong Chen, Yi Zhu, Youfei Guan, Fude Fang, Yongsheng Chang. Mouse PNPLA3 Influences Systemic Lipid and Glucose Homeostasis. Hepatology, 2011, Aug; 54(2): 509-21. (IF₂₀₂₂: 17.3)

9. Xiaojun Liu*, Aijun Qiao*, Yaojun Ke, Xingxing Kong, Jichao Liang, Rui Wang, XiaoqingOuyang, Jin Zuo, Yongsheng Chang, Fude fang. FoxO1 Represses LXRα-Mediated Transcriptional Activity of SREBP-1c Promoter in HepG2 Cells. FEBS Lett, 2010, 20(584): 4330-4334. (*共第一作者，IF₂₀₂₁: 4.1)

10. 岳桂华*，朱智德*，乔爱君*.《心内科新医师手册（第三版）》，2017. 化学工业出版社. (*主编).